HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

PI3K/AKT/mTOR pathway inhibitors: the ideal combination partners for breast cancer therapies?

Abstract
Activation of the phosphatidylinositol 3-kinase (PI3K)/AKT/mTOR pathway is common in breast cancer. PI3K pathway activation has been associated with tumor growth and progression, and thus is a promising target for breast cancer therapy. Agents targeting the PI3K pathway can restore sensitivity to standard breast cancer therapies, including endocrine, HER2-targeted agents and chemotherapy, by suppressing PI3K pathway activation, which is central to the development of therapeutic resistance. The combination of endocrine therapy and PI3K pathway (mTOR) inhibition has proven clinical benefit, and novel combination strategies involving PI3K pathway inhibitors and other investigational targeted therapies are now being explored clinically in patients with breast cancer.
AuthorsJame Abraham
JournalExpert review of anticancer therapy (Expert Rev Anticancer Ther) Vol. 15 Issue 1 Pg. 51-68 (Jan 2015) ISSN: 1744-8328 [Electronic] England
PMID25306975 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
Chemical References
  • Antineoplastic Agents
  • Phosphoinositide-3 Kinase Inhibitors
  • Proto-Oncogene Proteins c-akt
  • TOR Serine-Threonine Kinases
Topics
  • Antineoplastic Agents (therapeutic use)
  • Breast Neoplasms (drug therapy)
  • Female
  • Humans
  • Phosphoinositide-3 Kinase Inhibitors
  • Proto-Oncogene Proteins c-akt (antagonists & inhibitors)
  • Signal Transduction
  • TOR Serine-Threonine Kinases (antagonists & inhibitors)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: